Eight devices get 515(i) data deadline changed to Feb. 14, 1998.
This article was originally published in The Gray Sheet
FOUR CARDIOPULMONARY DEVICES TO RECEIVE EXTENSION OF 515(i) deadline for submission of safety and effectiveness data from August 14, 1997 to February 14, 1998. The four devices -- sorbent hemoperfusion system, artificial embolization device, cardiopulmonary bypass arterial line blood filter and cardiopulmonary bypass oxygenator -- are among eight products for which FDA is modifying the deadline for the submission of device information under section 515(i) of the Food, Drug and Cosmetic Act to Feb. 14, 1998. The agency is preparing a Federal Register notice announcing the changed deadlines.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.